Very good Energy13 Jan 2024 11:45
Here it is
the last paragraph
As biotechs step up their therapeutic research, like London-based clinical-stage company Avacta, which received orphan drug status for its chemotherapy drug doxorubicin AVA6000 for soft tissue sarcoma last year, treatment options are expanding. And the fact that the hard-to-diagnose disease is both fast-metastasizing and deadly, demands all the more research into drug development.